Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Trovan Suspension Recommended In EU; Distribution Limited In U.S.

Executive Summary

A 12-month suspension of Pfizer's Trovan has been recommended by the European Union's Committee for Proprietary Medicinal Products. Pfizer plans to appeal the decision.

You may also be interested in...



Medical Advances Get More Chances When Safety Issues Arise

Withdrawn “me too” NMEs were removed from the market sooner after post-marketing safety signals than first-in-class or advance-in-class NMEs, showing the importance of available alternative therapy (or the lack thereof) in post-marketing risk management decisions.

FDA Launches Phase IV Tracking System; Baseline Is 20% Completion Rate

FDA's Phase IV tracking system shows a 20% completion rate for postmarketing commitments

FDA Launches Phase IV Tracking System; Baseline Is 20% Completion Rate

FDA's Phase IV tracking system shows a 20% completion rate for postmarketing commitments

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel